Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BMYBristol-Myers SquibbFinished

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

Cancer, Hepatocellular

3Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Sep 9, 2026 · was worth 5, fading over time

    +2.6
Worry score3

Score over time

Stage
Phase 3
Patients
26 (final count)
Started
Sep 14, 2020
Main results expected
Dec 12, 2023
Fully finished
Dec 12, 2023
Results posted
Nov 26, 2024

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Number of Participants With Adverse Events

    Measured over: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  • Number of Participants With Serious Adverse Events (SAEs)

    Measured over: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  • Number of Participants Who Died

    Measured over: From first dose and 100 days after last dose of study therapy (up to approximately 27 months)

  • Number of Participants With Adverse Events Leading to Study Drug Discontinuation

    Measured over: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  • Number of Participants With Worst Grade (Grade 3/4) Laboratory Results

    Measured over: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  • Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    Measured over: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  • Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests

    Measured over: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT04340193 · record last updated 2024-11-26 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04340193) ↗